Reap Leo, Goldman Lyle
Ascension Providence Hospital.
Michigan State University College of Human Medicine.
Leuk Res Rep. 2020 Oct 6;14:100225. doi: 10.1016/j.lrr.2020.100225. eCollection 2020.
Leukemic transformation of myelodysplastic syndrome (MDS) or chronic myelogenous leukemia (CML) is a well-established phenomenon. However, co-occurrence of MDS and CML is a rare phenomenon, with few reports to date. Though blast crisis typically occurs systemically with MDS or CML, rare reports of focal transformation with myeloid sarcoma (MS) have been described. We present the first known case of concomitant MDS and CML on imatinib that developed focal blastic transformation, where the leukemic clone was BCR-ABL1 positive. Local irradiation and second-generation TKI was enough to attain long-term remission. Herein, we discuss MS and its implications in both CML and MDS.
骨髓增生异常综合征（MDS）或慢性粒细胞白血病（CML）向白血病转化是一种已被充分证实的现象。然而，MDS和CML同时出现是一种罕见现象，迄今为止报道较少。虽然原始细胞危象通常在MDS或CML中全身发生，但也有少数关于髓系肉瘤（MS）局部转化的报道。我们报告了首例已知的在接受伊马替尼治疗的同时患有MDS和CML并发生局部原始细胞转化的病例，其中白血病克隆为BCR-ABL1阳性。局部放疗和第二代酪氨酸激酶抑制剂足以实现长期缓解。在此，我们讨论MS及其在CML和MDS中的意义。
